[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Abrahão M, Gonçalves AP, Yamashita R, Dedivitis RA, Santos RO, Nascimento LA, Mudo ML, Ferraz FA, Cervantes O: Frontal sinus adenocarcinoma. Sao Paulo Med J; 2000 Jul 6;118(4):118-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontal sinus adenocarcinoma.
  • CONTEXT: Paranasal sinus cancer is considered rare, with an incidence of less than 1 per 100,000 per year, with the frontal sinus being the primary site in only 0.3%.
  • We report a case of adenocarcinoma arising in the frontal sinus.
  • CT scan showed a soft-tissue mass involving frontal sinus with intracranial invasion through the posterior wall.
  • The anterior ethmoid sinus and the medial aspect of the right orbit were also involved.
  • Histology revealed an adenocarcinoma.
  • After surgery she had tumor recurrence, and chemotherapy and radiotherapy were started resulting in partial improvement.
  • [MeSH-major] Adenocarcinoma / diagnosis. Frontal Sinus. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10887389.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] BRAZIL
  •  go-up   go-down


2. Kamiński B, Kobiorska-Nowak J, Bień S: [Distant metastases to nasal cavities and paranasal sinuses, from the organs outside the head and neck]. Otolaryngol Pol; 2008;62(4):422-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distant metastases to nasal cavities and paranasal sinuses, from the organs outside the head and neck].
  • At that time, the correct diagnosis requires only to compare the pathology report from the primary biopsy, with the biopsy from the lump in the head and neck.
  • The metastases to nasal cavity and paranasal sinuses are very rare and usually localized within the maxillary sinus.
  • MATERIAL: 4 cases, out of 46 all distant metastases to the head and neck region, localized in the nasal cavity and paranasal sinuses, diagnosed and treated in Dept. of ORL H&N surgery, Holy Cross Cancer Centre, from 2001 to 2007.
  • Case I. F. 71 years; the metastasis of colonic carcinoma to the sphenoid sinus as a first symptom of the disease).
  • The palliative Rtg-therapy was applied, and patient died in 2 months after diagnosis was established.
  • Patient was treated with multiple courses of chemotherapy due to generalization of the disease.
  • Cases III. F. 50 years in palliative stage of the breast cancer, with metastases to the bones and hepar and with metastasis to the maxillary sinus.
  • Received palliative Rtg. therapy on the region of metastasis.
  • Died in 5 months after diagnosis of maxillary sinus metastasis.
  • Case IV. F. 54 years in palliative stage of the colonic cancer, with multiple metastases to the lungs and hepar; with metastasis to the maxillary sinus.
  • During hemotherapy a symptoms of tumor of the maxillary sinus appeared, confirmed as a metastasis.
  • The palliative Rtg-therapy on the region of metastasis.
  • Died in 18 months, after diagnosis of maxillary sinus metastasis.
  • CONCLUSIONS: The prognosis of metastases from distant organs, to the nasal cavity and paranasal sinuses is miserable.
  • In the majority of distant metastases to the nose and paranasal sinuses, the palliative therapy is the only possible option of treatment.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Renal Cell / pathology. Colonic Neoplasms / pathology. Paranasal Sinus Neoplasms / secondary. Skull Base Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Poland. Prognosis. Survival Analysis. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837216.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


3. Huang CT, Hong RL: Nasion swelling as the presenting symptom of lung adenocarcinoma. J Thorac Oncol; 2009 Apr;4(4):555-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasion swelling as the presenting symptom of lung adenocarcinoma.
  • Metastasis to the paranasal sinuses from lung cancer is extremely rare.
  • Here, we reported a patient of lung adenocarcinoma presenting with nasion swelling because of metastasis to the paranasal sinuses.
  • Adenocarcinoma was the most commonly encountered histologic subtype, and modern combination chemotherapy was probably the most effective treatment modality.
  • Headache, visual disturbance, facial mass, and facial pain were the symptoms frequently associated with paranasal sinus metastasis; however, all of them were nonspecific for a metastatic tumor.
  • A thorough history taking, ear, nose, and throat examination, and laboratory investigations are of paramount importance to achieve a correct diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Paranasal Sinus Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333075.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


Advertisement
4. Torrico Román P, Mogollón Cano-Cortés T, López-Ríos Velasco J, Fernández de Mera JJ, Blasco Huelva A: [Bladder transitional cell carcinoma with metastasis to the maxillary sinus as first symptom]. Acta Otorrinolaringol Esp; 2001 Oct;52(7):622-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder transitional cell carcinoma with metastasis to the maxillary sinus as first symptom].
  • Maxillary sinus metastasis are very uncommon tumors (fifty have been reported).
  • The most frequent ones are renal adenocarcinoma, breast and lung tumors.
  • Up to now there is only a reported case of bladder carcinoma in maxillary sinus.
  • The treatment was chemotherapy.
  • We reported some considerations about metastatic tumors of paranasal sinus.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Maxillary Sinus Neoplasms / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11692954.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, Cheesman A, De Sa G, Donald P, Fliss DM, Gullane P, Janecka I, Kamata SE, Kowalski LP, Levine PA, Medina Dos Santos LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP: Craniofacial resection for malignant paranasal sinus tumors: Report of an International Collaborative Study. Head Neck; 2005 Jul;27(7):575-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniofacial resection for malignant paranasal sinus tumors: Report of an International Collaborative Study.
  • One hundred eighty-eight patients (56.3%) had had prior single-modality or combined treatment, which included surgery in 120 (36%), radiation in 79 (23.7%), and chemotherapy in 56 (16.8%).
  • The most common histologic findings were adenocarcinoma in 107 (32%) and squamous cell carcinoma in 101 (30.2%).
  • Adjuvant radiotherapy was given in 161 (48.2%) and chemotherapy in 16 (4.8%).
  • Statistical analyses for outcomes were performed in relation to patient characteristics, tumor characteristics, including histologic findings and extent of disease, surgical resection margins, prior radiation, and prior chemotherapy to determine predictive factors.
  • CONCLUSIONS: CFR for malignant paranasal sinus tumors is a safe surgical treatment with an overall mortality of 4.5% and complication rate of 33%.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Paranasal Sinus Neoplasms / surgery. Skull / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cohort Studies. Female. Follow-Up Studies. Humans. International Cooperation. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Postoperative Complications. Skull Base / pathology. Skull Base / surgery. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15825201.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


6. Nagano H, Yoshifuku K, Deguchi K, Kurono Y: Adenocarcinoma of the paranasal sinuses and nasal cavity with lung metastasis showing complete response to combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF): a case report. Auris Nasus Larynx; 2010 Apr;37(2):238-43
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the paranasal sinuses and nasal cavity with lung metastasis showing complete response to combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF): a case report.
  • Malignant tumors in the paranasal sinuses and nasal cavity are mostly squamous cell carcinomas, with comparatively few adenocarcinomas.
  • Adenocarcinoma developing in paranasal sinuses and nasal cavity generally has a low response to radiotherapy and low chemotherapeutic sensitivity, making surgery the most reliable treatment.
  • However, advanced adenocarcinoma is often difficult to treat due to anatomical complexity, and the outcome may not be satisfactory.
  • Adenocarcinoma was diagnosed by open biopsy.
  • Six courses of chemotherapy by super-selective intra-arterial infusion of cisplatin with concurrent intensity-modulated radiation therapy of 70Gy were performed at another hospital.
  • However, the tumor enlarged and developed distant metastasis to the lung after this therapy.
  • Therefore, TPF chemotherapy (docetaxel, cisplatin and 5-fluorouracil) was performed 5 times, after which the tumor gradually reduced in size.
  • The patient is alive after a follow-up period of 43 months, indicating that TPF chemotherapy may be useful for adenocarcinoma of the paranasal sinuses and nasal cavity.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Nose Neoplasms / drug therapy. Paranasal Sinus Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19560300.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Llarena Ibarguren R, García-Olaverri Rodríguez J, Villafruela Mateos A, Azurmendi Arin I, Olano Grasa I, Pertusa Peña C: [Metastases in the paranasal sinuses secondary to prostatic adenocarcinoma]. Arch Esp Urol; 2007 Nov;60(9):1.137-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastases in the paranasal sinuses secondary to prostatic adenocarcinoma].
  • [Transliterated title] Metástasis en senos paranasales secundaria a adenocarcinoma prostático.
  • METHODS: 64-year-old male with nine months history of disseminated prostate cancer, taking hormonal treatment and biphosphonates, who presents with rising PSA, facial dysesthesia and left exophtalmos.
  • MRI recognizes the existence of a solid mass in the right maxillary sinus with involvement of the ipsilateral orbital floor, and another one in the left frontal sinus invading the roof of the ipsilateral orbit and also with orbital extraconal involvement.
  • RESULTS: Once the diagnosis was established hormonal maneuvers were performed and chemotherapy with docetaxel was administered achieving at the start of treatment measurable disease stabilization with biochemical remission of PSA levels, followed posteriorly by progression without changes in the metastatic images.
  • Currently new cytoreductive therapy with docetaxel has been initiated.
  • Most frequent metastases are localized in the brain and meninges, being the involvement of paranasal sinuses and ocular orbit extraordinary.
  • Second line hormonal maneuvers, local radiotherapy and systemic chemotherapy will be necessary for control, although results are discouraging.
  • [MeSH-major] Adenocarcinoma / secondary. Paranasal Sinus Neoplasms / secondary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077874.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. Licitra L, Suardi S, Bossi P, Locati LD, Mariani L, Quattrone P, Lo Vullo S, Oggionni M, Olmi P, Cantù G, Pierotti MA, Pilotti S: Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol; 2004 Dec 15;22(24):4901-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
  • PURPOSE: To assess the role of TP53 status in predicting pathologic complete remission after primary chemotherapy in patients with ethmoidal intestinal-type adenocarcinoma (ITAC).
  • PATIENTS AND METHODS: Thirty patients with ethmoidal ITAC enrolled onto a phase II study received chemotherapy with cisplatin, fluorouracil, and leucovorin (PFL) followed by surgery and radiation.
  • In patients with wild-type (wt) TP53 or functional p53 protein, the pCRs were 83% and 80%, respectively; in patients with mutated TP53 or impaired p53 protein, pCRs were 11% and 0%, respectively (P < or = .0001).
  • CONCLUSION: The results indicate the existence of two genetic ITAC subgroups, defined by differences in TP53 mutational status or protein functionality, that strongly influence pathologic response to primary chemotherapy and, ultimately, prognosis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ethmoid Sinus / pathology. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / genetics. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. DNA Mutational Analysis. Female. Fluorouracil / administration & dosage. Forecasting. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Male. Middle Aged. Predictive Value of Tests. Prognosis. Prospective Studies. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15611505.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Jansen EP, Keus RB, Hilgers FJ, Haas RL, Tan IB, Bartelink H: Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma? Int J Radiat Oncol Biol Phys; 2000 Aug 1;48(1):27-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma?
  • PURPOSE: To determine the contribution of debulking surgery on local control and survival in paranasal sinus tumors.
  • METHODS AND MATERIALS: Between 1977 and 1996, 73 patients (50 male: 23 female) with a paranasal sinus carcinoma were treated.
  • The histology distribution was as follows: squamous cell carcinoma, 55%; adenocarcinoma, 19%; adenoid cystic carcinoma, 11%; and undifferentiated carcinoma, 15%.
  • Treatment consisted of surgery only in 3, chemotherapy only in 1, radiotherapy only in 18, both surgery and radiotherapy in 50 patients.
  • One patient did not receive any treatment at all.
  • Three patients had concurrent chemotherapy.
  • However, combination treatment gave significantly better 5-year overall survival (OS) (60% vs. 9%; p = 0.001) and 5-year disease-free survival (DFS) (53% vs. 6%; p < 0. 0001).
  • Cox-regression analysis showed that pathologic N status (p = 0.04), palliative intention of treatment (p = 0.018), clinical orbital invasion (p = 0.003), and orbital wall invasion (p = 0.003) were parameters significantly associated with poor local control.
  • Total radiation dose of greater than 65 Gy (p = 0.05) and treatment consisting of radiotherapy alone (p = 0.002) were associated with worse overall survival; for disease-free survival clinical orbital invasion (p = 0.0005), age of greater than 65 years (p = 0.013) and pathologic T4 classification (p = 0.002) were significant factors for an unfavorable outcome.
  • In 19 of 73 patients, 26 serious (mainly ophthalmological) complications were reported; in the majority of these, the visual tract was (partly) included in the treatment fields because of tumor extension.
  • To analyze on which basis patients were selected for the combination therapy, a logistic regression was performed, concluding that clinical T4 classification (p = 0.05), radiological evidence of skull base invasion (p = 0.005), age of greater than 65 years (p = 0.026), radiological evidence of nasopharynx invasion (p = 0.02), clinical suspicion of palate invasion (p = 0.02), and radiological evidence of skin invasion (p = 0.009) were associated with choosing radiotherapy alone.
  • CONCLUSION: Debulking surgery of paranasal sinus malignancies followed by high-dose radiotherapy to the involved sites was associated with better survival and (although not statistically significant) local control.
  • We favor this combination regimen because the surgery gives quick relief of complaints and, at the same time, offers an excellent histologically proven staging method, enabling radiotherapy to be adjusted to the involved sites, thereby decreasing the risk of complications.
  • [MeSH-major] Paranasal Sinus Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Analysis of Variance. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / radiotherapy. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Cause of Death. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / mortality. Radiation Injuries / therapy. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10924968.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


10. Day TA, Beas RA, Schlosser RJ, Woodworth BA, Barredo J, Sharma AK, Gillespie MB: Management of paranasal sinus malignancy. Curr Treat Options Oncol; 2005 Jan;6(1):3-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of paranasal sinus malignancy.
  • Malignancies of the nasal cavity and paranasal sinuses represent a wide spectrum of histologies, tissues of origin, and anatomic primary sites.
  • The inherent difficulty in generalizing treatment approaches is obvious, given the numerous variables associated with the broadly-based term, paranasal sinus malignancy (PNSCa).
  • Nevertheless, the majority of epithelial and salivary malignancies of this region (ie, squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, sinonasal undifferentiated carcinoma, and esthesioneuroblastoma) require surgical intervention as part of any treatment regimen.
  • Nonepithelial malignancies, including the wide variety of sarcomas arising in this region, most commonly require multimodality treatment including chemotherapy, radiation, and/or surgery for definitive treatment.
  • Moreover, the proximity of the nasal cavity and paranasal sinuses to structures including the orbit, dura, brain, cranial nerves, and carotid arteries mandates careful radiologic and neurologic evaluations throughout the course of the disease.
  • However, additional clinical trials are necessary to systematically evaluate the locoregional control, organ-preservation strategies, and survival related to the variety of treatments currently available.
  • [MeSH-major] Carcinoma / surgery. Melanoma / surgery. Paranasal Sinus Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Age Factors. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Diet. Humans. Life Style. Prognosis. Radiotherapy, Adjuvant. Reconstructive Surgical Procedures

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):486-91 [12243826.001]
  • [Cites] Head Neck. 1995 Jul-Aug;17(4):303-11 [7672971.001]
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Med Pediatr Oncol. 1999 Oct;33(4):362-71 [10491544.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):335-41 [14716769.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):219-23 [10439167.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):371-6 [11859210.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):948-55 [15313865.001]
  • [Cites] Head Neck Surg. 1980 May-Jun;2(5):410-9 [7364592.001]
  • [Cites] Am J Otolaryngol. 2004 May-Jun;25(3):162-6 [15124164.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1157-62 [11583200.001]
  • [Cites] Oral Oncol. 2002 Jul;38(5):450-9 [12110339.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 15;128(2):130-6 [11463451.001]
  • [Cites] Laryngoscope. 2002 Oct;112(10):1871-6 [12368633.001]
  • [Cites] Oncology (Williston Park). 2000 Nov;14(11A):163-94 [11195409.001]
  • [Cites] Otolaryngol Clin North Am. 1995 Dec;28(6):1239-57 [8927395.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Jul;129(1):77-84 [12869921.001]
  • [Cites] Otolaryngol Clin North Am. 2004 Apr;37(2):473-87 [15064075.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):751-8 [12117328.001]
  • [Cites] Nature. 1987 Oct 15-21;329(6140):645-7 [3657988.001]
  • [Cites] Am J Rhinol. 2002 Jul-Aug;16(4):221-7 [12222948.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):158-68 [12694834.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Mar;3(2):84-9 [2031888.001]
  • [Cites] Am J Rhinol. 2002 Sep-Oct;16(5):281-6 [12422974.001]
  • [Cites] Stereotact Funct Neurosurg. 2004;82(2-3):84-9 [15305080.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):944-8 [12975266.001]
  • [Cites] Oncology (Williston Park). 1992 Jan;6(1):43-50; discussion 55-6 [1531603.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):361-9 [9607352.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):283-9 [9308929.001]
  • [Cites] Ear Nose Throat J. 2002 Aug;81(8):510-4, 516-7 [12199167.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):594-611 [12717245.001]
  • [Cites] Laryngoscope. 2000 Apr;110(4):635-40 [10764010.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):290-4 [11452937.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jul 1;136(1):53-7 [12165452.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1405-10 [11870186.001]
  • [Cites] Strahlenther Onkol. 2003 Apr;179(4):233-40 [12707712.001]
  • [Cites] Head Neck. 2004 Feb;26(2):136-44 [14762882.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):197-201 [11936913.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):204-13 [10623711.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jul;119(7):743-6 [8318204.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):147-54 [14697432.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Feb;47(1):9-15 [15100926.001]
  • [Cites] Acta Otorhinolaryngol Belg. 1996;50(1):19-24 [8669267.001]
  • [Cites] Laryngoscope. 2003 Dec;113(12):2086-90 [14660907.001]
  • [Cites] Am J Surg Pathol. 1986 Mar;10 (3):192-202 [3953940.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5108-12 [8221646.001]
  • [Cites] Head Neck. 2004 May;26(5):435-41 [15122660.001]
  • [Cites] Head Neck. 2003 Oct;25(10):791-8 [12966502.001]
  • [Cites] Head Neck Surg. 1980 Jul-Aug;2(6):497-508 [6248488.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Acta Otorhinolaryngol Belg. 2000;54(2):221-32 [10892511.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Jan;3(1):17-21 [1705815.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):823-9 [9369129.001]
  • [Cites] Epidemiology. 1998 Sep;9(5):518-24 [9730030.001]
  • [Cites] Eur J Nucl Med. 2001 Jul;28(7):816-21 [24770459.001]
  • [Cites] J Laryngol Otol. 1992 Dec;106(12):1063-6 [1487661.001]
  • [Cites] J Neurosurg. 1995 Jun;82(6):1002-10 [7760173.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Sep;128(9):1079-83 [12220216.001]
  • [Cites] Laryngoscope. 2002 Aug;112(8 Pt 1):1450-5 [12172261.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):208-10 [10439164.001]
  • [Cites] Head Neck. 1994 Nov-Dec;16(6):574-7 [7822181.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1101-7 [14652810.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Mar;129(3):334-7 [12622544.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1700-11 [10547542.001]
  • [Cites] Head Neck. 2004 Apr;26(4):322-30 [15054735.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):657-61 [1730116.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):255-64 [10421261.001]
  • [Cites] J Laryngol Otol. 1998 Jul;112(7):628-33 [9775291.001]
  • [Cites] Head Neck. 2002 Sep;24(9):821-9 [12211046.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3743-9 [11268448.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Head Neck. 2004 Jul;26(7):584-93 [15229900.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):167-86 [15062368.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):147-57 [11936821.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Mar;120(3):387-90 [10064643.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):776-84 [12573765.001]
  • [Cites] Radiother Oncol. 1991 Jul;21(3):193-200 [1924855.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):932-7 [15333652.001]
  • [Cites] Cancer. 2003 Apr 25;99(2):105-12 [12704690.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Dec;34(6):1241-57, xi [11728944.001]
  • [Cites] Am J Epidemiol. 1994 Aug 15;140(4):340-9 [8059769.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):367-72 [12598339.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1597-604 [12459626.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):1964-9 [12439163.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):101-7 [10361593.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Feb;47(1):1-8 [15100925.001]
  • [Cites] Minim Invasive Neurosurg. 2003 Oct;46(5):310-5 [14628249.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):318-31 [11567805.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • (PMID = 15610711.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


11. Porceddu S, Martin J, Shanker G, Weih L, Russell C, Rischin D, Corry J, Peters L: Paranasal sinus tumors: Peter MacCallum Cancer Institute experience. Head Neck; 2004 Apr;26(4):322-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paranasal sinus tumors: Peter MacCallum Cancer Institute experience.
  • BACKGROUND: The purpose of this study was to evaluate the local control, pattern of recurrence, overall survival, and prognostic factors of patients with squamous cell carcinoma (SCC), adenocarcinoma, and undifferentiated carcinoma of the paranasal sinuses (PNS) and nasal cavity (NC) presenting to our center for curative treatment over a 10-year period.
  • METHODS: Between 1991 and 2000, 60 patients with SCC (n = 32), adenocarcinoma (n = 25), and undifferentiated carcinoma (n = 3) of the PNS or NC were identified.
  • Forty patients received surgery and postoperative radiotherapy, four surgery alone; 11, radiotherapy alone; three radical radiotherapy after surgical recurrence; one, chemoradiotherapy and surgery; and one, induction chemotherapy followed by radiotherapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Australia / epidemiology. Blindness / etiology. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Nervous System Neoplasms / secondary. Orbital Neoplasms / secondary. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • Genetic Alliance. consumer health - Sinus cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc.
  • (PMID = 15054735.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Padovani L, Pommier P, Clippe S S, Martel-Lafay I, Malet C, Poupart M, Zrounba P, Ceruse P, Desmes S, Carrie C, Montbarbon X, Ginestet C: Three-dimensional conformal radiotherapy for paranasal sinus carcinoma: clinical results for 25 patients. Int J Radiat Oncol Biol Phys; 2003 May 1;56(1):169-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional conformal radiotherapy for paranasal sinus carcinoma: clinical results for 25 patients.
  • PURPOSE: To assess local control, survival, and clinical and dosimetric prognostic factors in 25 patients with locally advanced maxillary or ethmoid sinus carcinoma treated by three-dimensional conformal radiotherapy (RT).
  • Seven patients received chemotherapy (concomitant with RT in four).
  • The following quality indexes were defined for the 95% and 90% isodoses: tumor conformity index, normal tissue conformity index, and global conformity index.
  • RESULTS: The median radiation dose to the planned treatment volume was 63 Gy, with a minimal dose of 60 Gy, except in 2 patients whose cancer progressed during RT.
  • After a median follow-up of 25 months, 14 local tumor recurrences developed.
  • Two patients died of acute infectious toxicity, and two developed late ipsilateral ocular toxicity.
  • CONCLUSIONS: Improving local control remains the main challenge in RT for paranasal tumors.
  • [MeSH-major] Carcinoma / radiotherapy. Imaging, Three-Dimensional. Paranasal Sinus Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Radiation. Ethmoid Sinus. Eye Injuries / etiology. Eye Injuries / prevention & control. Female. Follow-Up Studies. Humans. Life Tables. Male. Maxillary Sinus Neoplasms / drug therapy. Maxillary Sinus Neoplasms / mortality. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / surgery. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Optic Nerve Injuries / etiology. Optic Nerve Injuries / prevention & control. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Radiotherapy Dosage. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694835.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Hameed S, Jamshed A, Hussain R, Ali M, Iqbal H, Majeed U, Shah MA: Neoadjuvant chemotherapy followed by radiotherapy or chemoradiation for locally advanced nasal and paranasal sinus tumors. J Clin Oncol; 2009 May 20;27(15_suppl):6055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by radiotherapy or chemoradiation for locally advanced nasal and paranasal sinus tumors.
  • : 6055 Background: The treatment of locally advanced nasal and paranasal sinus tumors is controversial.
  • The disease is chemosensitive and there is increasing interest in the use of chemotherapy with radiation in this group of patients.
  • Our aim was to determine survival in patients with locally advanced nasal and paranasal sinus tumors treated with neoadjuvant chemotherapy followed by radiotherapy or chemoradiation (RT/CRT).
  • METHODS: Between August 2005 and August 2008, 21 patients with AJCC stage III or IV nasal and paranasal sinus tumors were treated with neoadjuvant chemotherapy followed by RT/CRT in our institution.
  • Site of disease was nasal cavity 33% (7), ethamoid sinus 43% (9), maxillary antrum 19% (4), and frontal sinus in 5% (1) of patients.
  • Histopathological diagnosis was squamous cell carcinoma 43% (9), undifferentiated carcinoma 29% (6), adenocarcinoma 19% (4), esthesioneuroblastoma in 9% (2) of patients.
  • Induction chemotherapy consisted of cisplatin 75 mg / metre<sup>2</sup> day 1 and gemcitabine 1 gm / metre<sup>2</sup> day 1 and 8 every three weeks.
  • Eighty-five percent (18/21) received 2 cycles of neoadjuvant chemotherapy (range 1-4 cycles) prior to radiotherapy.
  • Radiotherapy dose was 54 Gy - 70 Gy (median radiation dose 66 Gy).
  • RESULTS: Response to neoadjuvant chemotherapy; complete in 19% (4), partial in 67% (14), no response/progression 14% (3).
  • Thirty-three percent (7/21) have failed treatment (local 3, regional 2, and distant metastasis in 2 patients).
  • Among treatment failures 2 patients were successfully salvaged; surgery for local recurrence in one patient and in the other case radiation was given for regional recurrence.
  • CONCLUSIONS: Gemcitabine cisplatin chemotherapy has good activity in nasal and paranasal sinus tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961932.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Blanco AI, Chao KS, Ozyigit G, Adli M, Thorstad WL, Simpson JR, Spector GJ, Haughey B, Perez CA: Carcinoma of paranasal sinuses: long-term outcomes with radiotherapy. Int J Radiat Oncol Biol Phys; 2004 May 1;59(1):51-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of paranasal sinuses: long-term outcomes with radiotherapy.
  • PURPOSE: To assess the clinical features, prognostic factors, results, and complications of treatment of carcinomas of the paranasal sinus.
  • METHODS AND MATERIALS: The records of 106 patients (72 men and 34 women) with paranasal sinus carcinoma treated with curative intent at Washington University between January 1960 and August 1998 were analyzed.
  • Most tumors originated in the maxillary (76%) or ethmoid (18%) sinus.
  • All patients underwent radiotherapy (RT), combined with surgery in 65%; 2% received chemotherapy.
  • CONCLUSION: This review of a large, single-institution experience of paranasal sinus carcinoma patients who underwent RT showed that locoregional tumor progression and recurrence remain predominant patterns of failure despite aggressive local treatment with combined surgery and RT.
  • DFS improved slightly with combined modality treatment.
  • The overall survival rates remained suboptimal, suggesting a need for more accurate determination of tumor extent, as well as more effective locoregional and systemic therapies.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Ethmoid Sinus. Female. Follow-Up Studies. Humans. Male. Maxillary Sinus Neoplasms / radiotherapy. Middle Aged. Prognosis. Proportional Hazards Models. Radiation Injuries / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15093898.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Knegt PP, Ah-See KW, vd Velden LA, Kerrebijn J: Adenocarcinoma of the ethmoidal sinus complex: surgical debulking and topical fluorouracil may be the optimal treatment. Arch Otolaryngol Head Neck Surg; 2001 Feb;127(2):141-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the ethmoidal sinus complex: surgical debulking and topical fluorouracil may be the optimal treatment.
  • OBJECTIVES: To report our experience with the management of adenocarcinoma of the ethmoidal sinuses using a regimen of surgical debulking and topical chemotherapy, to report long-term survival, and to compare our results with recently published series of patients undergoing craniofacial resection.
  • PATIENTS: Seventy consecutive patients with ethmoidal adenocarcinoma referred to the Department of Head and Neck Surgery, University Hospital of Rotterdam, Rotterdam, the Netherlands, between January 1976 and December 1997.
  • Sixty-two patients were eligible for primary treatment.
  • INTERVENTIONS: Surgical debulking via an extended anterior maxillary antrostomy followed by a combination of repeated topical chemotherapy (fluorouracil) and necrotomy.
  • Clinical complications related to the therapy.
  • One patient (1.6%) developed meningitis.
  • CONCLUSION: Our 23-year experience with a combination of surgical debulking and repeated topical chemotherapy for patients with adenocarcinoma of the ethmoidal sinuses leads us to believe that it represents the current treatment of choice for these patients for long-term disease-free survival.
  • [MeSH-major] Adenocarcinoma / therapy. Ethmoid Sinus. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11177030.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Kiprian D: [Strategy of combined treatment in patient with cancer of paranasal sinuses]. Otolaryngol Pol; 2007;61(4):527-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Strategy of combined treatment in patient with cancer of paranasal sinuses].
  • Other types of cancer in this region are adenocarcinoma (about 30%), carcinoma adenoides cysticum or neoplasms such as rhabdosarcoma, chondrosarcoma, lymphoma or melanoma malignum.
  • Cancer of the paranasal sinuses infiltrates only locoregionally.
  • Metastases to the lymph nodes are seldom--below 30%; this is why elective lymphangiectomy or irradiation are not obligatory treatment in this case.
  • The treatment of cancers of paranasal sinuses is always surgery with adjuvant irradiation.
  • The modern radiotherapy techniques provide the possibility to spare healthy tissues and organs at risk.
  • The radiation treatment combined with chemotherapy is applied in cases of not radical surgery in the region of ethmoides sinuses.
  • [MeSH-major] Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Incidence. Neoplasm Staging. Radiotherapy, Conformal. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260245.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 5
  •  go-up   go-down


17. Madison Michael L 2nd, Sorenson JM, Samant S, Robertson JH: The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation. J Neurooncol; 2005 Mar;72(1):67-75
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation.
  • INTRODUCTION: Malignancies of the nasal and paranasal sinuses are uncommon tumors, accounting for only 3% of all aerodigestive tract neoplasms.
  • Despite advances in surgical techniques and continued evolution of adjuvant therapies, the 5-year mortality remains unusually high at greater than 50%.
  • In 1996, we begin utilizing a novel strategy in the treatment of advanced sinonasal carcinomas.
  • This consisted of neoadjuvant selective intra-arterial cisplatin with concurrent radiation therapy (acronym RADPLAT) followed by a conservative craniofacial resection.
  • METHODS: Between July 1996 and April 2003, 11 patients with advanced sinonasal malignancies underwent treatment utilizing the RADPLAT protocol followed by a planned surgical resection via a craniofacial approach.
  • CONCLUSIONS: The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation results in a significant improvement in survival.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Carcinoma / radiotherapy. Cisplatin / administration & dosage. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoadjuvant Therapy / methods. Premedication. Radiation-Sensitizing Agents / administration & dosage. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):263-71 [9226312.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 20;85(2):95-111 [8418313.001]
  • [Cites] Head Neck. 1998 Mar;20(2):97-105 [9484939.001]
  • [Cites] Am J Surg. 1987 Oct;154(4):352-8 [3661836.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Apr;118(4):367-72 [1313248.001]
  • [Cites] Acta radiol. 1954 Aug;42(2):149-72 [13197115.001]
  • [Cites] Otolaryngol Clin North Am. 1995 Dec;28(6):1239-57 [8927395.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jan;14 (1):11-22 [3335447.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jun;127(6):687-90 [11405869.001]
  • [Cites] Head Neck. 2000 Oct;22(7):687-93 [11002324.001]
  • [Cites] Head Neck Surg. 1986 Jul-Aug;8(6):429-35 [3721885.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):765-73 [7960977.001]
  • [Cites] Am J Surg. 1988 Sep;156(3 Pt 1):187-90 [3421426.001]
  • [Cites] J Neurosurg. 1968 Apr;28(4):341-50 [5643926.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):361-9 [9607352.001]
  • [Cites] Am J Surg. 1985 Oct;150(4):406-13 [4051102.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):190-6 [3965080.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):457-65 [9690538.001]
  • [Cites] AMA Arch Otolaryngol. 1953 Dec;58(6):704-9 [13103898.001]
  • [Cites] Cancer. 1963 Oct;16:1293-301 [14074213.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Nov;120(11):1203-8 [7917203.001]
  • [Cites] Head Neck. 2000 Dec;22(8):772-80 [11084637.001]
  • [Cites] Acta Oncol. 1997;36(1):27-31 [9090960.001]
  • [Cites] Head Neck. 1994 Jul-Aug;16(4):307-12 [8056574.001]
  • [Cites] Radiol Med. 1994 Sep;88(3):291-4 [7938737.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Feb;127(2):141-6 [11177030.001]
  • [Cites] Curr Oncol Rep. 2001 Jan;3(1):59-65 [11123871.001]
  • [Cites] J Clin Oncol. 1986 Jul;4(7):1121-6 [3522819.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):419-22 [7977964.001]
  • [Cites] Radiother Oncol. 1998 Oct;49(1):21-7 [9886693.001]
  • [Cites] J Otolaryngol. 1978 Oct;7(5):379-88 [105151.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jul;119(7):743-6 [8318204.001]
  • [Cites] Laryngoscope. 1989 Nov;99(11):1130-6 [2811551.001]
  • [Cites] Semin Oncol. 1994 Oct;21(5 Suppl 12):28-34 [7992064.001]
  • [Cites] Cancer. 1986 Jun 15;57(12):2261-6 [3697928.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):10-5 [2738628.001]
  • [Cites] Oncology (Williston Park). 1997 Dec;11(12):1781-90, 1796; discussion 1796, 179 [9436185.001]
  • [Cites] Cancer. 1954 Sep;7(5):991-4 [13199776.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1989 Apr;115(4):503-11 [2466470.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Laryngoscope. 1994 May;104(5 Pt 1):553-5 [8189985.001]
  • [Cites] Head Neck Surg. 1988 Mar-Apr;10(4):219-24 [3235351.001]
  • [Cites] Head Neck. 1999 May;21(3):185-91 [10208659.001]
  • [Cites] Neurosurgery. 2000 Dec;47(6):1296-304; discussion 1304-5 [11126900.001]
  • [Cites] Am J Surg. 1973 Oct;126(4):469-76 [4743833.001]
  • [Cites] Head Neck. 1994 Nov-Dec;16(6):574-7 [7822181.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Aug;13(4):769-75, vii [10494512.001]
  • [Cites] Neurosurgery. 1996 Mar;38(3):471-9; discussion 479-80 [8837798.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Dec;127(12):1451-6 [11735813.001]
  • [Cites] J Otolaryngol. 1984 Jun;13(3):141-6 [6100551.001]
  • [Cites] Laryngoscope. 1994 Aug;104(8 Pt 1):940-5 [8052078.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3333-9 [11454880.001]
  • [Cites] J Craniofac Surg. 1997 Sep;8(5):405-12 [9482083.001]
  • [Cites] Radiother Oncol. 2000 Nov;57(2):167-73 [11054520.001]
  • [Cites] Semin Oncol. 1991 Feb;18(1 Suppl 3):34-48 [2003226.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):838-47 [8622032.001]
  • [Cites] Ann Intern Med. 1982 Dec;97(6):845-51 [6890785.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Apr;25(4):619-25 [2714338.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1476-82 [11920504.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):541-9 [10701732.001]
  • [Cites] Am Surg. 1990 May;56(5):327-30 [2334076.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):83-91 [7819055.001]
  • [Cites] Cancer. 1985 Jul 1;56(1):57-62 [4005793.001]
  • [Cites] Am J Surg. 1989 Oct;158(4):328-32 [2802037.001]
  • [Cites] J Am Med Assoc. 1948 Aug 7;137(15):1306; passim [18870026.001]
  • [Cites] Cancer Commun. 1990;2(2):93-100 [2372473.001]
  • [Cites] Am J Surg. 1963 Nov;106:698-703 [14078719.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):755-63 [7960976.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan;25(1):113-6 [8416866.001]
  • [Cites] Head Neck Surg. 1983 Jul-Aug;5(6):508-13 [6885504.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):1964-9 [12439163.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1925-32 [11064349.001]
  • [Cites] Am J Surg. 1966 Oct;112(4):591-6 [5915306.001]
  • (PMID = 15803378.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M: Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg; 2009 Dec;135(12):1219-24
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: All patients with biopsy-proved malignant neoplasm of the sinonasal region who were treated with endoscopic resection between 1992 and 2007 were included in the study, and their charts were reviewed for demographics, histopathologic findings, treatment details, and outcome.
  • Of the 120 patients, 41% presented with previously untreated disease, 46% presented with persistent disease that had been partially resected, and 13% presented with recurrent disease after prior treatment.
  • However, the T-stage distribution was significantly different between the EEA group and the CEA group.
  • The most common tumor types were esthesioneuroblastoma (17%), sarcoma (15%), adenocarcinoma (14%), melanoma (14%), and squamous cell carcinoma (13%).
  • Of the 120 patients, 50% were treated with surgery alone, 37% received postoperative radiation therapy, and 13% were treated with surgery, radiation therapy, and chemotherapy.
  • Our results suggest that, in well-selected patients and with appropriate use of adjuvant therapy, endoscopic resection of sinonasal cancer results in acceptable oncologic outcomes.
  • [MeSH-major] Endoscopy. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Craniotomy. Disease-Free Survival. Esthesioneuroblastoma, Olfactory / surgery. Ethmoid Sinus. Female. Humans. Male. Melanoma / surgery. Middle Aged. Neoplasm Recurrence, Local. Nose Neoplasms / mortality. Nose Neoplasms / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026819.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Vedrine PO, Thariat J, Merrot O, Percodani J, Dufour X, Choussy O, Toussaint B, Dassonville O, Klossek JM, Santini J, Jankowski R: Primary cancer of the sphenoid sinus--a GETTEC study. Head Neck; 2009 Mar;31(3):388-97
Genetic Alliance. consumer health - Sinus cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cancer of the sphenoid sinus--a GETTEC study.
  • BACKGROUND: Primary involvement of the sphenoid sinus occurs in 2% of all paranasal sinus tumors and is associated with dismal prognosis.
  • METHODS: A total of 23 patients were treated for a primary cancer of the sphenoid sinus from 1988 to 2004.
  • Charts were reviewed for patient-, tumor-, and treatment-related parameters.
  • Pathologic findings included adenoid cystic carcinoma, adenocarcinoma, lymphoma, squamous cell carcinoma, sarcoma, neuroendocrine carcinoma, melanoma, and malignant hemangiopericytoma.
  • Radiotherapy was performed in 18 patients and chemotherapy in 12.
  • Surgery was rarely complete because of advanced stages at presentation, but it yielded better outcomes than other treatments without surgery in non lymphoma-cases.
  • Surgery, including debulking surgery, may be preferred to combined modality treatments without surgery.
  • Highly conformal radiotherapy (adjuvant or definitive) should be encouraged and optimized with concurrent chemotherapy in advanced stages.
  • Aggressive multidisciplinary management including surgery, chemotherapy, and radiotherapy should be encouraged and adapted on histology and tumor extensions.
  • [MeSH-major] Paranasal Sinus Neoplasms / mortality. Paranasal Sinus Neoplasms / therapy. Sphenoid Sinus / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / mortality. Carcinoma / pathology. Carcinoma / therapy. Chemotherapy, Adjuvant. Cranial Nerve Diseases / complications. Diagnostic Imaging. Female. Humans. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Male. Melanoma / mortality. Melanoma / pathology. Melanoma / therapy. Meningioma / mortality. Meningioma / pathology. Meningioma / therapy. Middle Aged. Multivariate Analysis. Plasmacytoma / mortality. Plasmacytoma / pathology. Plasmacytoma / therapy. Preoperative Care. Radiotherapy, Adjuvant. Radiotherapy, Conformal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18972425.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


20. Guillotte-van Gorkum ML, Nasser T, Mérol JC, Legros M, Rousseaux P, Chays A: [Ethmoid adenocarcinoma: a series of 17 cases]. Ann Otolaryngol Chir Cervicofac; 2003 Nov;120(5):296-301

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ethmoid adenocarcinoma: a series of 17 cases].
  • INTRODUCTION: Ethmoid adenocarcinoma are and represent rare, 2.5 to 3% of head and neck cancers.
  • OBJECTIVES: Expose the treatment of these patients and evaluate the results.
  • METHODS: A retrospective study of 17 consecutive patients, treated between 1992 and 1999 for an ethmoid adenocarcinoma (15 T4 and 2 T2) and evaluated in 2002, with a mean follow-up of 5.8 years.
  • Most teams agree that postoperative radiotherapy is necessary but the appropriateness of chemotherapy is still discussed.
  • Some authors are of the opinion that it has no action on adenocarcinoma and others that it improves survival.
  • [MeSH-major] Adenocarcinoma / therapy. Ethmoid Sinus. Paranasal Sinus Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14726849.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


21. Airoldi M, Garzaro M, Valente G, Mamo C, Bena A, Giordano C, Pecorari G, Gabriele P, Gabriele AM, Beatrice F: Clinical and biological prognostic factors in 179 cases with sinonasal carcinoma treated in the Italian Piedmont region. Oncology; 2009;76(4):262-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with T1-T2 adenocarcinoma and squamous cell cancers (SCC) had better median survival than those with other lesions (p < 0.05).
  • Patients treated with surgery with or without radiotherapy had better survival (p < 0.01), while chemotherapy had a marginally favorable effect (p = 0.09).
  • The type of surgery and radiotherapy dose had no impact on survival; in contrast, there was a strong association between Ki-67 expression and microvessel density and overall survival (p < 0.05 and p = 0.039, respectively), while VEGF-C was a prognostic factor in SCC patients only (p < 0.05).
  • CONCLUSIONS: In sinonasal cancer, tumor stage and histology have a clear impact on survival; surgery with or without radiotherapy represents the main choice of treatment for such tumors.
  • [MeSH-major] Paranasal Sinus Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD31 / analysis. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Vascular Endothelial Growth Factor C / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19258726.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


22. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB: Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck; 2002 Sep;24(9):821-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant tumors of the nasal cavity and paranasal sinuses.
  • PURPOSE: To evaluate the role of radiation therapy in patients with nasal cavity and paranasal sinus tumors.
  • MATERIALS AND METHODS: Between October 1964 and July 1998, 78 patients with malignant tumors of the nasal cavity (48 patients), ethmoid sinus (24 patients), sphenoid sinus (5 patients), or frontal sinus (1 patient) were treated with curative intent by radiation therapy alone or in the adjuvant setting.
  • There were 25 squamous cell carcinomas, 14 undifferentiated carcinomas, 31 minor salivary gland tumors (adenocarcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma), 8 esthesioneuroblastomas, and 1 transitional cell carcinoma.
  • Forty-seven patients were treated with irradiation alone, 25 with surgery and postoperative irradiation, 2 with preoperative irradiation and surgery, and 4 with chemotherapy in combination with irradiation with or without surgery.
  • Of the 67 (86%) patients who were initially seen with node-negative disease, 39 (58%) received no elective neck treatment, and 28 (42%) received elective neck irradiation.
  • Of the 39 patients who received no elective neck treatment, 33 (85%) did not experience recurrence in the neck compared with 25 (89%) of 28 patients who received elective neck irradiation.
  • CONCLUSION: Surgery and postoperative radiation therapy may result in improved local control, absolute survival, and complications when compared with radiation therapy alone.
  • [MeSH-major] Carcinoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blindness / etiology. Blindness / prevention & control. Cause of Death. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Osteoradionecrosis / etiology. Postoperative Care. Preoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc. Head Neck 24: 821-829, 2002
  • (PMID = 12211046.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Brasnu D, Roux FX: [Cancer of the ethmoid sinus]. Rev Prat; 2000 Sep 15;50(14):1562-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer of the ethmoid sinus].
  • Seventy to 80% of the ethmoid sinus malignant tumors are adenocarcinomas.
  • Wood dust exposure is a carcinogen agent to ethmoid adenocarcinoma.
  • More than 90% of patients with ethmoid adenocarcinoma are woodworkers.
  • Craniofacial computed tomography scan and magnetic resonance imaging are always performed before treatment.
  • It is always a multidisciplinary treatment including surgical resection followed by external radiation therapy.
  • Some authors recommend a neoadjuvant chemotherapy.
  • Local recurrence is the most frequent cause of failure; 5-year survival of patients with ethmoid adenocarcinoma is around 50%.
  • [MeSH-major] Adenocarcinoma. Ethmoid Sinus. Paranasal Sinus Neoplasms
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Fluorouracil / administration & dosage. Humans. Magnetic Resonance Imaging. Postoperative Care. Prognosis. Radiotherapy, Adjuvant. Time Factors

  • Genetic Alliance. consumer health - Sinus cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11068621.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] FRANCE
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Babin E, Rouleau V, Vedrine PO, Toussaint B, de Raucourt D, Malard O, Cosmidis A, Makaeieff M, Dehesdin D: Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses. J Laryngol Otol; 2006 Apr;120(4):289-97
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses.
  • OBJECTIVE: Report a descriptive study of a relatively large cohort of SNEC of the nasal cavity and paranasal sinuses.
  • METHOD: The medical records of 21 patients presenting with nasal and paranasal SNEC to various French hospitals, from 1989 to 2003, were analysed to determine the clinical features and current treatment of the disease.
  • Immunohistochemistry proved useful for diagnosis in 20 cases.
  • One patient had an adenocarcinoma and an inverted papilloma associated with neuroendocrine carcinoma.
  • Patients underwent surgery (11 cases), radiotherapy (14 cases) and chemotherapy (12 cases).
  • However, the current treatment of these neuroendocrine neoplasms varies widely.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology. Nasal Cavity / pathology. Nose Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Paranasal Sinuses / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16526967.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


25. Uchida D, Shirato H, Onimaru R, Endou H, Aoyama H, Tsuchiya K, Nishioka T, Homma A, Furuta Y, Fukuda S, Miyasaka K: Long-term results of ethmoid squamous cell or undifferentiated carcinoma treated with radiotherapy with or without surgery. Cancer J; 2005 Mar-Apr;11(2):152-6
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Ethmoidal malignant tumors, for which intensity-modulated radiotherapy is expected to improve outcome, consist of heterogeneous pathological types.
  • Reports about their outcome are influenced by the inclusion of favorable histology, such as adenocarcinoma and adenoid cystic carcinoma.
  • We investigated the long-term treatment outcome of squamous cell carcinoma and undifferentiated carcinoma of the ethmoid sinus.
  • Radiation dose varied from 50.4 Gy in 16 fractions (50.4 Gy/16 Fr) to 65 Gy in 26 fractions with or without stereotactic boost irradiation.
  • Eleven patients received chemotherapy consisting mainly of platinum-based compounds.
  • CONCLUSION: Ethmoid squamous cell carcinoma or undifferentiated carcinoma was diagnosed at advanced T stages and was treated with radiotherapy; these patients had a poorer outcome than patients with adenocarcinoma or adenoid cystic carcinoma.
  • Prospective trials using advanced technology should be carefully compared with historical controls because pathological types can considerably influence the treatment results.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Ethmoid Sinus / pathology. Paranasal Sinus Neoplasms / radiotherapy. Treatment Outcome
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15969991.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Llorente JL, Pérez-Escuredo J, Alvarez-Marcos C, Suárez C, Hermsen M: Genetic and clinical aspects of wood dust related intestinal-type sinonasal adenocarcinoma: a review. Eur Arch Otorhinolaryngol; 2009 Jan;266(1):1-7
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and clinical aspects of wood dust related intestinal-type sinonasal adenocarcinoma: a review.
  • Intestinal-type sinonasal adenocarcinoma (ITAC) is a rare epithelial cancer of the nasal cavities and paranasal sinuses.
  • Standard therapeutic modalities include surgery followed by radiotherapy in advanced stages, sometimes with chemotherapy treatment.
  • Histopathologically, ITAC resembles colorectal adenocarcinoma and have directed early genetic studies to search for similar genetic alterations.
  • This review aims to describe the clinico-pathological characteristics of this relatively unknown tumor and to summarize the knowledge on genetic and chromosomal analyses up to the present time.
  • [MeSH-major] Adenocarcinoma / etiology. Neoplasm Recurrence, Local / pathology. Occupational Exposure / adverse effects. Paranasal Sinus Neoplasms / etiology. Wood / adverse effects
  • [MeSH-minor] Dust. Female. Genetic Predisposition to Disease / epidemiology. Humans. Immunohistochemistry. Male. Molecular Biology. Neoplasm Staging. Prognosis. Survival Analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Apoptosis. 2004 Mar;9(2):123-30 [15004509.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):335-41 [14716769.001]
  • [Cites] Surg Neurol. 1994 Aug;42(2):98-104 [8091301.001]
  • [Cites] Arch Otorhinolaryngol. 1988;245(1):1-15 [2839136.001]
  • [Cites] J Otolaryngol. 1993 Apr;22(2):86-90 [8515523.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1345-57 [15001537.001]
  • [Cites] Head Neck. 1998 May;20(3):224-31 [9570628.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4901-6 [15611505.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10 ):1080-3 [15452164.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):315-9 [15492756.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):740-2 [10699958.001]
  • [Cites] Acta Otolaryngol Suppl. 1998;535:1-16 [9725790.001]
  • [Cites] Mod Pathol. 1995 May;8(4):421-6 [7567943.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1109-19 [12360473.001]
  • [Cites] Br Med J. 1968 Jun 8;2(5605):587-96 [5654629.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Feb;127(2):141-6 [11177030.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Jul;135(1):135-9 [16815198.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):99-106 [15068833.001]
  • [Cites] Head Neck. 2004 Feb;26(2):136-44 [14762882.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):197-201 [11936913.001]
  • [Cites] Acta Otorhinolaryngol Belg. 1996;50(1):19-24 [8669267.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Jul;122(7):765-8 [8663951.001]
  • [Cites] Cell. 2004 Sep 17;118(6):671-4 [15369667.001]
  • [Cites] Am J Surg Pathol. 1986 Mar;10 (3):192-202 [3953940.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4817-25 [15256451.001]
  • [Cites] Carcinogenesis. 2005 Sep;26(9):1513-9 [15860506.001]
  • [Cites] Acta Otolaryngol. 1986 May-Jun;101(5-6):501-8 [3727983.001]
  • [Cites] Acta Otorrinolaringol Esp. 2008 May;59(5):235-8 [18501159.001]
  • [Cites] Acta Otorrinolaringol Esp. 2004 Jan;55(1):27-33 [15108619.001]
  • [Cites] Laryngoscope. 2008 Mar;118(3):437-43 [18176354.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2154-9 [18186150.001]
  • [Cites] Am J Surg Pathol. 1982 Dec;6(8):803-9 [7168462.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):255-64 [10421261.001]
  • [Cites] Head Neck. 2006 Oct;28(10 ):909-15 [16906516.001]
  • [Cites] Am J Otolaryngol. 1995 Mar-Apr;16(2):109-14 [7793504.001]
  • [Cites] J Pathol. 2005 Oct;207(2):207-15 [16041693.001]
  • [Cites] Mod Pathol. 1996 Mar;9(3):199-204 [8685214.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):196-203 [12673679.001]
  • [Cites] Am J Epidemiol. 1994 Aug 15;140(4):340-9 [8059769.001]
  • [Cites] Acta Otolaryngol. 1984 Sep-Oct;98(3-4):321-34 [6496064.001]
  • [Cites] Cancer Lett. 1998 Apr 10;126(1):59-65 [9563649.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):482-8 [6733678.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1988 Sep;114(9):996-9 [3408582.001]
  • (PMID = 18560862.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dust
  • [Number-of-references] 47
  •  go-up   go-down


27. Lund V, Howard DJ, Wei WI: Endoscopic resection of malignant tumors of the nose and sinuses. Am J Rhinol; 2007 Jan-Feb;21(1):89-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The procedure was performed under frozen section control.
  • Thirty-seven cases underwent radiotherapy and 14 cases underwent adjuvant chemotherapy.
  • A wide range of pathologies included 15 cases of adenocarcinoma, 11 malignant melanomas, and 11 olfactory neuroblastomas.
  • [MeSH-major] Endoscopy / methods. Nose Neoplasms / surgery. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Length of Stay. Magnetic Resonance Imaging. Male. Middle Aged. Prospective Studies. Survival Rate. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283568.001).
  • [ISSN] 1050-6586
  • [Journal-full-title] American journal of rhinology
  • [ISO-abbreviation] Am J Rhinol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Chen AM, Daly ME, Bucci MK, Xia P, Akazawa C, Quivey JM, Weinberg V, Garcia J, Lee NY, Kaplan MJ, El-Sayed I, Eisele DW, Fu KK, Phillips TL: Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement? Int J Radiat Oncol Biol Phys; 2007 Sep 1;69(1):141-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement?
  • PURPOSE: To compare clinical outcomes of patients with carcinomas of the paranasal sinuses and nasal cavity according to decade of radiation treatment.
  • METHODS AND MATERIALS: Between 1960 and 2005, 127 patients with sinonasal carcinoma underwent radiotherapy with planning and delivery techniques available at the time of treatment.
  • Nineteen patients (15%) received chemotherapy.
  • There were no significant differences in any of these endpoints with respect to decade of treatment or radiotherapy technique (p > 0.05, for all).
  • CONCLUSION: Although we did not detect improvements in disease control or overall survival for patients treated over time, the incidence of complications has significantly declined, thereby resulting in an improved therapeutic ratio for patients with carcinomas of the paranasal sinuses and nasal cavity.
  • [MeSH-major] Nasal Cavity. Nose Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / radiotherapy. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiation Injuries / prevention & control. Radiotherapy / adverse effects. Radiotherapy / trends. Radiotherapy, Conformal / adverse effects. Radiotherapy, Intensity-Modulated / adverse effects. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459609.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement